In today’s briefing:
- APAC Healthcare Weekly (Aug 17) – Fosun Pharma, Remegen, Astellas, Daewoong Pharma, Zydus, Lupin
- Europe Trip Summary (Off-Topic)
APAC Healthcare Weekly (Aug 17) – Fosun Pharma, Remegen, Astellas, Daewoong Pharma, Zydus, Lupin
- Fosun Pharma outlicensed XH-S004 to Expedition Therapeutics for $120M upfront and milestone payment. Remegen’s drug candidate met primary endpoint in Phase 3 trial for Sjögren’s syndrome in China.
- Astellas Pharma announced positive topline results from the Phase 3 trial evaluating Padcev in bladder cancer. Daewoong Pharmaceutical announced positive result for their self-developed semaglutide microneedle patch.
- Zydus Lifesciences received FDA approval for chest pain drug Diltiazem Hydrochloride tablets. Lupin has partnered with Sandoz to market and commercialize Lupin’s biosimilar ranibizumab across multiple regions.
Europe Trip Summary (Off-Topic)
- Traveled across Berlin, Prague, Mykonos, and Athens, experiencing the contrast of Germany’s modernity, Prague’s historic charm, and Greece’s mix of island leisure with urban revival.
- Tourism is booming in both the Czech Republic and Greece, with record visitor numbers driving economic confidence, hotel expansion, and rising foreign investment into related industries.
- Equity markets in the Czech Republic and Greece have been among the world’s best performers, fueled by strong banks, reforms, dividend payouts, and surging investor inflows.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
